Antimicrobial resistance at a crossroads: the cost of inaction
- PMID: 39265589
- PMCID: PMC11476572
- DOI: 10.1016/S0140-6736(24)01705-7
Antimicrobial resistance at a crossroads: the cost of inaction
Conflict of interest statement
The findings and conclusions in this Comment are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention. We declare no competing interests.
References
-
- Hutchings M, Truman A, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol 2019; 51: 72–80. - PubMed
-
- Centers for Disease Control and Prevention. 2022 Special report: COVID-19—U.S. impact on antimicrobial resistance. 2022. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf (accessed Aug 12, 2024).
-
- Nanayakkara A, Boucher H, Fowler V Jr, Jezek A, Outterson K, Greenberg DE. Antibiotic resistance in the patient with cancer: escalating challenges and paths forward. CA Cancer J Clin 2021; 71: 488–504. - PubMed
-
- Jona O, Irwin A, Berthe F, Le Gall F, Marquez P. Drug-resistant infections: a threat to our economic future (vol 2): final report. World Bank. 2017. http://documents.worldbank.org/curated/en/323311493396993758/final-report (accessed Aug 12, 2024).
Grants and funding
LinkOut - more resources
Full Text Sources
